Home
    Disclaimer
    ← Back to 4-AcO-DPT
    4-AcO-DPT molecular structure

    4-AcO-DPT Stats & Data

    Psychedelic Research-chemical
    Depracetin 4acodpt
    NPS DataHub
    MW302.42
    FormulaC18H26N2O2
    CAS1445751-75-6
    IUPAC3-(2-(dipropylamino)ethyl)-1H-indol-4-yl acetate
    SMILESCCCN(CCC)CCc1cnc2cccc(OC(C)=O)c12
    InChIKeyKRUGABVNKKKCJN-UHFFFAOYSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT2A receptor agonist (partial)
    5-HT2C receptor agonist (partial)

    Effect Profile

    Curated + 5 Reports
    Psychedelic 4.4

    Moderate visuals with mild body load and headspace

    Visual Intensity×3
    6
    Headspace Depth×3
    4
    Auditory Effects×1
    0
    Body Load / Somatic Effects×1
    5
    Based on reports from:
    Effect Index Greater Mind Lesser Body — nervewing Erowid Experience Reports PsychonautWiki 4-AcO-DPT

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    30% ●○○
    Psilocybin
    30% ●○○
    Psilocin
    30% ●○○
    Mescaline
    30% ●○○
    DMT
    30% ●○○
    5-MeO-DMT
    30% ●○○
    2C-B
    30% ●○○
    2C-E
    30% ●○○

    Experience Report Analysis

    Erowid
    5 Reports
    2012–2020 Date Range
    4 With Age Data
    9 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 5 experience reports (5 Erowid)

    5 Reports
    9 Effects Detected
    7 Positive
    1 Adverse
    1 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 7

    Color Enhancement 100.0% 70%
    Stimulation 100.0% 70%
    Euphoria 60.0% 70%
    Introspection 60.0% 70%
    Empathy 60.0% 70%
    Focus Enhancement 60.0% 70%
    Tactile Enhancement 60.0% 70%

    Adverse Effects 1

    Anxiety 80.0% 70%

    Real-World Dose Distribution

    62K Doses

    From 5 individual dose entries

    Insufflated (n=5)

    Median: 20.0mg 25th: 20.0mg 75th: 25.0mg 90th: 28.0mg

    Form / Preparation

    Most common forms and preparations reported

    Read full reports on Erowid →

    References

    Data Sources

    Cited References

    ← Back to 4-AcO-DPT